Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Mapping phospho-catalytic dependencies of therapy-resistant tumours reveals actionable vulnerabilities.

Coppé JP, Mori M, Pan B, Yau C, Wolf DM, Ruiz-Saenz A, Brunen D, Prahallad A, Cornelissen-Steijger P, Kemper K, Posch C, Wang C, Dreyer CA, Krijgsman O, Lee PRE, Chen Z, Peeper DS, Moasser MM, Bernards R, van 't Veer LJ.

Nat Cell Biol. 2019 Jun;21(6):778-790. doi: 10.1038/s41556-019-0328-z. Epub 2019 Jun 3.

PMID:
31160710
2.

A Dimerization Function in the Intrinsically Disordered N-Terminal Region of Src.

Spassov DS, Ruiz-Saenz A, Piple A, Moasser MM.

Cell Rep. 2018 Oct 9;25(2):449-463.e4. doi: 10.1016/j.celrep.2018.09.035.

3.

HER2 Amplification in Tumors Activates PI3K/Akt Signaling Independent of HER3.

Ruiz-Saenz A, Dreyer C, Campbell MR, Steri V, Gulizia N, Moasser MM.

Cancer Res. 2018 Jul 1;78(13):3645-3658. doi: 10.1158/0008-5472.CAN-18-0430. Epub 2018 May 14.

4.

Regulation of inside-out β1-integrin activation by CDCP1.

Pollan SG, Huang F, Sperger JM, Lang JM, Morrissey C, Cress AE, Chu CY, Bhowmick NA, You S, Freeman MR, Spassov DS, Moasser MM, Carter WG, Satapathy SR, Shah K, Knudsen BS.

Oncogene. 2018 May;37(21):2817-2836. doi: 10.1038/s41388-018-0142-2. Epub 2018 Mar 7.

PMID:
29511352
5.

Targeting HER2 by Combination Therapies.

Ruiz-Saenz A, Moasser MM.

J Clin Oncol. 2018 Mar 10;36(8):808-811. doi: 10.1200/JCO.2017.77.1899. Epub 2018 Jan 30. No abstract available.

6.

CD318 is a ligand for CD6.

Enyindah-Asonye G, Li Y, Ruth JH, Spassov DS, Hebron KE, Zijlstra A, Moasser MM, Wang B, Singer NG, Cui H, Ohara RA, Rasmussen SM, Fox DA, Lin F.

Proc Natl Acad Sci U S A. 2017 Aug 15;114(33):E6912-E6921. doi: 10.1073/pnas.1704008114. Epub 2017 Jul 31.

7.

Retraction Notice to: An ATP-Competitive Inhibitor Modulates the Allosteric Function of the HER3 Pseudokinase.

Littlefield P, Moasser MM, Jura N.

Cell Chem Biol. 2017 Jul 20;24(7):917. doi: 10.1016/j.chembiol.2017.07.008. No abstract available.

8.

A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies.

Chien AJ, Cockerill A, Fancourt C, Schmidt E, Moasser MM, Rugo HS, Melisko ME, Ko AH, Kelley RK, Korn WM, Esserman LJ, van't Veer L, Yau C, Wolf DM, Munster PN.

Breast Cancer Res Treat. 2016 Feb;155(3):521-30. doi: 10.1007/s10549-016-3701-7. Epub 2016 Feb 13.

PMID:
26875185
9.

Effective treatment of HER2-amplified breast cancer by targeting HER3 and β1 integrin.

Campbell MR, Zhang H, Ziaee S, Ruiz-Saenz A, Gulizia N, Oeffinger J, Amin DN, Ahuja D, Moasser MM, Park CC.

Breast Cancer Res Treat. 2016 Feb;155(3):431-40. doi: 10.1007/s10549-016-3698-y. Epub 2016 Feb 9.

10.

Chemical probing of HER2-amplified cancer cells identifies TORC2 as a particularly effective secondary target for combination with lapatinib.

Amin DN, Ruiz-Saenz A, Gulizia N, Moasser MM.

Oncotarget. 2015 Dec 1;6(38):41123-33. doi: 10.18632/oncotarget.5660.

11.

A TORC2-Akt Feed-Forward Topology Underlies HER3 Resiliency in HER2-Amplified Cancers.

Amin DN, Ahuja D, Yaswen P, Moasser MM.

Mol Cancer Ther. 2015 Dec;14(12):2805-17. doi: 10.1158/1535-7163.MCT-15-0403. Epub 2015 Oct 5.

12.

The Evolving Landscape of HER2 Targeting in Breast Cancer.

Moasser MM, Krop IE.

JAMA Oncol. 2015 Nov;1(8):1154-61. doi: 10.1001/jamaoncol.2015.2286. Review.

PMID:
26204261
13.

Disentangling multidimensional spatio-temporal data into their common and aberrant responses.

Chang YH, Korkola J, Amin DN, Moasser MM, Carmena JM, Gray JW, Tomlin CJ.

PLoS One. 2015 Apr 22;10(4):e0121607. doi: 10.1371/journal.pone.0121607. eCollection 2015.

14.

Targeting HER3 by interfering with its Sec61-mediated cotranslational insertion into the endoplasmic reticulum.

Ruiz-Saenz A, Sandhu M, Carrasco Y, Maglathlin RL, Taunton J, Moasser MM.

Oncogene. 2015 Oct 8;34(41):5288-94. doi: 10.1038/onc.2014.455. Epub 2015 Jan 26.

15.

HER Targeting in HER2-Negative Breast Cancers: Looking for the HER3 Positive.

Campbell MR, Moasser MM.

Clin Cancer Res. 2015 Jul 1;21(13):2886-8. doi: 10.1158/1078-0432.CCR-14-3012. Epub 2015 Jan 21.

16.

A multilevel model of postmenopausal breast cancer incidence.

Hiatt RA, Porco TC, Liu F, Balke K, Balmain A, Barlow J, Braithwaite D, Diez-Roux AV, Kushi LH, Moasser MM, Werb Z, Windham GC, Rehkopf DH.

Cancer Epidemiol Biomarkers Prev. 2014 Oct;23(10):2078-92. doi: 10.1158/1055-9965.EPI-14-0403. Epub 2014 Jul 13.

17.

Two dimensions in targeting HER2.

Moasser MM.

J Clin Oncol. 2014 Jul 1;32(19):2074-7. doi: 10.1200/JCO.2014.55.7652. Epub 2014 May 27. No abstract available.

18.

Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer.

Chien AJ, Munster PN, Melisko ME, Rugo HS, Park JW, Goga A, Auerback G, Khanafshar E, Ordovas K, Koch KM, Moasser MM.

J Clin Oncol. 2014 May 10;32(14):1472-9. doi: 10.1200/JCO.2013.52.1161. Epub 2014 Apr 7.

19.

RETRACTED: An ATP-competitive inhibitor modulates the allosteric function of the HER3 pseudokinase.

Littlefield P, Moasser MM, Jura N.

Chem Biol. 2014 Apr 24;21(4):453-458. doi: 10.1016/j.chembiol.2014.02.011. Epub 2014 Mar 20. Retraction in: Cell Chem Biol. 2017 Jul 20;24(7):917.

20.

Trask loss enhances tumorigenic growth by liberating integrin signaling and growth factor receptor cross-talk in unanchored cells.

Spassov DS, Wong CH, Wong SY, Reiter JF, Moasser MM.

Cancer Res. 2013 Feb 1;73(3):1168-79. doi: 10.1158/0008-5472.CAN-12-2496. Epub 2012 Dec 12.

21.

HER3 signalling is regulated through a multitude of redundant mechanisms in HER2-driven tumour cells.

Amin DN, Sergina N, Lim L, Goga A, Moasser MM.

Biochem J. 2012 Nov 1;447(3):417-25. doi: 10.1042/BJ20120724.

22.

A tumor-suppressing function in the epithelial adhesion protein Trask.

Spassov DS, Wong CH, Harris G, McDonough S, Phojanakong P, Wang D, Hann B, Bazarov AV, Yaswen P, Khanafshar E, Moasser MM.

Oncogene. 2012 Jan 26;31(4):419-31. doi: 10.1038/onc.2011.246. Epub 2011 Jun 27.

23.

The structural features of Trask that mediate its anti-adhesive functions.

Spassov DS, Ahuja D, Wong CH, Moasser MM.

PLoS One. 2011 Apr 29;6(4):e19154. doi: 10.1371/journal.pone.0019154.

24.

Trask phosphorylation defines the reverse mode of a phosphotyrosine signaling switch that underlies cell anchorage state.

Spassov DS, Wong CH, Moasser MM.

Cell Cycle. 2011 Apr 15;10(8):1225-32. Epub 2011 Apr 15.

25.

Phosphorylation of Trask by Src kinases inhibits integrin clustering and functions in exclusion with focal adhesion signaling.

Spassov DS, Wong CH, Sergina N, Ahuja D, Fried M, Sheppard D, Moasser MM.

Mol Cell Biol. 2011 Feb;31(4):766-82. doi: 10.1128/MCB.00841-10. Epub 2010 Dec 28.

26.

The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics.

Amin DN, Campbell MR, Moasser MM.

Semin Cell Dev Biol. 2010 Dec;21(9):944-50. doi: 10.1016/j.semcdb.2010.08.007. Epub 2010 Sep 9. Review.

27.

Resiliency and vulnerability in the HER2-HER3 tumorigenic driver.

Amin DN, Sergina N, Ahuja D, McMahon M, Blair JA, Wang D, Hann B, Koch KM, Shokat KM, Moasser MM.

Sci Transl Med. 2010 Jan 27;2(16):16ra7. doi: 10.1126/scitranslmed.3000389.

28.

HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy.

Campbell MR, Amin D, Moasser MM.

Clin Cancer Res. 2010 Mar 1;16(5):1373-83. doi: 10.1158/1078-0432.CCR-09-1218. Epub 2010 Feb 23.

29.

A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies.

Chien AJ, Illi JA, Ko AH, Korn WM, Fong L, Chen LM, Kashani-Sabet M, Ryan CJ, Rosenberg JE, Dubey S, Small EJ, Jahan TM, Hylton NM, Yeh BM, Huang Y, Koch KM, Moasser MM.

Clin Cancer Res. 2009 Sep 1;15(17):5569-75. doi: 10.1158/1078-0432.CCR-09-0522. Epub 2009 Aug 25.

30.

MRI methods for evaluating the effects of tyrosine kinase inhibitor administration used to enhance chemotherapy efficiency in a breast tumor xenograft model.

Aliu SO, Wilmes LJ, Moasser MM, Hann BC, Li KL, Wang D, Hylton NM.

J Magn Reson Imaging. 2009 May;29(5):1071-9. doi: 10.1002/jmri.21737.

31.

The transmembrane src substrate Trask is an epithelial protein that signals during anchorage deprivation.

Spassov DS, Baehner FL, Wong CH, McDonough S, Moasser MM.

Am J Pathol. 2009 May;174(5):1756-65. doi: 10.2353/ajpath.2009.080890. Epub 2009 Apr 6.

32.

Phosphorylation of the SRC epithelial substrate Trask is tightly regulated in normal epithelia but widespread in many human epithelial cancers.

Wong CH, Baehner FL, Spassov DS, Ahuja D, Wang D, Hann B, Blair J, Shokat K, Welm AL, Moasser MM.

Clin Cancer Res. 2009 Apr 1;15(7):2311-22. doi: 10.1158/1078-0432.CCR-08-2533. Epub 2009 Mar 24.

33.

A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer.

Dickler MN, Rugo HS, Eberle CA, Brogi E, Caravelli JF, Panageas KS, Boyd J, Yeh B, Lake DE, Dang CT, Gilewski TA, Bromberg JF, Seidman AD, D'Andrea GM, Moasser MM, Melisko M, Park JW, Dancey J, Norton L, Hudis CA.

Clin Cancer Res. 2008 Dec 1;14(23):7878-83. doi: 10.1158/1078-0432.CCR-08-0141.

34.

HER-2-directed, small-molecule antagonists.

Arkin M, Moasser MM.

Curr Opin Investig Drugs. 2008 Dec;9(12):1264-76. Review.

35.

Cellular mechanisms of resistance to anthracyclines and taxanes in cancer: intrinsic and acquired.

Chien AJ, Moasser MM.

Semin Oncol. 2008 Apr;35(2 Suppl 2):S1-S14; quiz S39. doi: 10.1053/j.seminoncol.2008.02.010. Review.

PMID:
18410794
36.

The epidermal growth factor receptor family: biology driving targeted therapeutics.

Wieduwilt MJ, Moasser MM.

Cell Mol Life Sci. 2008 May;65(10):1566-84. doi: 10.1007/s00018-008-7440-8. Review.

37.

The HER family and cancer: emerging molecular mechanisms and therapeutic targets.

Sergina NV, Moasser MM.

Trends Mol Med. 2007 Dec;13(12):527-34. Epub 2007 Nov 5. Review.

38.

Improved tumor vascular function following high-dose epidermal growth factor receptor tyrosine kinase inhibitor therapy.

Moasser MM, Wilmes LJ, Wong CH, Aliu S, Li KL, Wang D, Hom YK, Hann B, Hylton NM.

J Magn Reson Imaging. 2007 Dec;26(6):1618-25.

39.

Targeting HER proteins in cancer therapy and the role of the non-target HER3.

Hsieh AC, Moasser MM.

Br J Cancer. 2007 Aug 20;97(4):453-7. Epub 2007 Jul 31. Review.

40.

Targeting the function of the HER2 oncogene in human cancer therapeutics.

Moasser MM.

Oncogene. 2007 Oct 11;26(46):6577-92. Epub 2007 May 7. Review.

41.
42.

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3.

Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, Moasser MM.

Nature. 2007 Jan 25;445(7126):437-41. Epub 2007 Jan 7.

43.

Adhesion signaling by a novel mitotic substrate of src kinases.

Bhatt AS, Erdjument-Bromage H, Tempst P, Craik CS, Moasser MM.

Oncogene. 2005 Aug 11;24(34):5333-43.

44.

A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane.

Modi S, Currie VE, Seidman AD, Bach AM, Panageas KS, Theodoulou M, Moasser MM, D'Andrea GM, Lake DE, Choi J, Norton L, Hudis CA.

Clin Breast Cancer. 2005 Apr;6(1):55-60.

PMID:
15899073
45.

Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments.

Dang CT, Dannenberg AJ, Subbaramaiah K, Dickler MN, Moasser MM, Seidman AD, D'Andrea GM, Theodoulou M, Panageas KS, Norton L, Hudis CA.

Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4062-7.

46.

S-phase inhibition of cell cycle progression by a novel class of pyridopyrimidine tyrosine kinase inhibitors.

Mizenina OA, Moasser MM.

Cell Cycle. 2004 Jun;3(6):796-803. Epub 2004 Jun 5.

PMID:
15136770
48.
49.

Farnesyl:protein transferase inhibitors as potential agents for the management of human prostate cancer.

Sepp-Lorenzino L, Tjaden G, Moasser MM, Timaul N, Ma Z, Kohl NE, Gibbs JB, Oliff A, Rosen N, Scher HI.

Prostate Cancer Prostatic Dis. 2001;4(1):33-43.

50.

The use of molecular markers in farnesyltransferase inhibitor (FTI) therapy of breast cancer.

Moasser MM, Rosen N.

Breast Cancer Res Treat. 2002 May;73(2):135-44.

PMID:
12088116

Supplemental Content

Loading ...
Support Center